Oxygen therapy has been delivered the same way for over a century - manually, inconsistently, and wrong roughly 50% of the time for critical patients. In this episode, we sat down with Marie-Louise Little, CEO of O2matic, to explore why that's finally changing.
Marie-Louise brings a rare dual perspective: an experienced MedTech investor and board member who crossed the table to lead the company she believed in. The conversation covers the clinical case for automated oxygen delivery, the real barriers to hospital adoption, and what it actually takes to build and scale a MedTech company from the inside.
